Last Week Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings

May 17, 2018 - By Lisa Delgado

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Corporate Logo

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Coverage

In total 3 analysts cover Adaptimmune Therapeutics (NASDAQ:ADAP). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:ADAP) has 100% bullish analysts. 3 are the (NASDAQ:ADAP)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Friday, March 16 Cowen & Co maintained Adaptimmune Therapeutics plc (NASDAQ:ADAP) with “Buy” rating. On Friday, March 16 the stock has “Buy” rating by Leerink Swann. Listed here are Adaptimmune Therapeutics plc (NASDAQ:ADAP) PTs and latest ratings.

16/03/2018 Broker: Cowen & Co Rating: Buy Maintain
16/03/2018 Broker: Raymond James Rating: Buy New Target: $20.0
16/03/2018 Broker: Leerink Swann Rating: Buy New Target: $15.0 Initiate

ADAP touched $12.14 during the last trading session after $0.17 change.Adaptimmune Therapeutics plc has volume of 124,066 shares. Since May 17, 2017 ADAP has risen 144.20% and is uptrending. ADAP outperformed by 132.65% the S&P500.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform.The firm is worth $1.14 billion. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients.Last it reported negative earnings. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

For more Adaptimmune Therapeutics plc (NASDAQ:ADAP) news published recently go to: Seekingalpha.com, Benzinga.com, Benzinga.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)” published on May 16, 2018, “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” on May 09, 2018, “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …” with a publish date: May 10, 2018, “Adaptimmune Reports First Quarter 2018 Financial Results and Business Update” and the last “Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American …” with publication date: May 16, 2018.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.